The latest news from academia, regulators
research labs and other things of interest
Posted: August 4, 2008
Midatech Announces Priority Nanoparticle Patent Granted by US
(Nanowerk News) Midatech Group, a leader in the production and application of synthetically produced nanoparticles, has received a US grant on its proprietary patent application (US09,622253), protecting the Company’s novel nanoparticle technology. The US Patent Office has issued allowance of 121 claims, placing Midatech as the global leader in nanotechnology for biological applications. Equivalent patent applications have previously been granted in Australia (AU2001294068) and Europe (EP1326589B).
More specifically, this patent covers the single-step process for the self-assembly of nanoparticles that contain a central core of a noble metal surrounded by a corona of biologically relevant ligands. Such nanoparticles have a range of unique characteristics that make them ideal for applications such as targeted drug delivery and diagnostic imaging. Superparamagnetic properties also allow for thermal heating and subsequent cell apoptosis upon application of an alternating radiofrequency electromagnetic field.
“The grant of this patent represents the cornerstone of Midatech’s nanotechnology IP portfolio and positions Midatech as the world leader in the development of nanoparticles for nanomedicine”, commented Professor Tom Rademacher, Chairman of Midatech Group. “This affirmation of our technology by the US Patent Office puts Midatech in an extremely strong position from which to engage in high value international collaborations in order to advance our nanoparticles into the clinic”.
Midatech’s nanoparticles are currently being used in a number of projects including targeted drug delivery for specific diseases, oncology, siRNA delivery, targeted cell killing (through radiofrequency heating), synthetic vaccine construction and medical imaging.
About Midatech Group
Midatech Group Ltd is a leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications that have the potential for multiple diagnostic and therapeutic applications.
Created in 2000 Midatech has IP covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas. As well as in-house product development it is prepared to licence this IP to 3rd Party pharmaceutical and diagnostic development partners whilst retaining manufacturing rights. Midatech has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles. The Company opened a cGMP standard design and manufacturing plant for nanocells – Midatech Biogune – in Bilbao, Spain in 2007.